ArticleExperimental & molecular medicine2026
Maresin1 improves cardiac dysfunction via LGR6 in heatstroke.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Heatstroke is a severe and life-threatening condition that can lead to cardiac dysfunction and poses a high risk of mortality. Maresin1, an endogenous lipid mediator, reportedly promotes inflammation resolution in various inflammatory diseases. However, its cardioprotective role during heatstroke has not been thoroughly investigated. In this study, we used ultra-performance liquid chromatography-tandem mass spectrometry to measure the levels of Maresin1 in the plasma and cardiac tissues of mice exposed to heatstroke. Our results indicated a notable decrease in Maresin1 levels under heatstroke conditions. In addition, the levels of leucine-rich repeat-containing G-protein-coupled receptor 6 (LGR6), a receptor for Maresin1, were increased in mice exposed to heatstroke. Exogenously administered Maresin1 significantly improved survival rates and alleviated the symptoms of heatstroke. Conversely, in Lgr6-knockout mice, the symptoms worsened, and the mortality rate increased. Transcriptomic analysis of the cardiac tissue and in vitro experiments have confirmed that Maresin1 exerts cardioprotective effects by inhibiting oxidative stress and promoting ATP synthesis through the upregulation of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α) mediated via LGR6. Nuclear respiratory factor 1 (NRF1) and nuclear respiratory factor 2 (NRF2) were also increased downstream, likely as a secondary response associated with improved mitochondrial biogenesis rather than direct transcriptional regulation by LGR6. Our findings indicate that the Maresin1-LGR6 axis serves a cardioprotective role in heatstroke and is a potential therapeutic target for heatstroke-induced cardiac dysfunction.
Identifiers
42827108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.